Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSCI / HK Connect June 2026 Implementation: Post-Implementation Review

HSCI / HK Connect June 2026 Implementation: Post-Announcement Positioning

HSCI / HK Connect May 2026 Review Forecast

HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>Following HSCI's quarterly review in May 2026, we expect six names to become HK Connect eligible effective 8 June 2026.</li>
<li>Four of these names fell through the bridge window. Two recorded positions returned in the pre-implementation window.</li>
<li>Historically, the implementation-day opening has been the moment to capture. The full first week for prior Connect ADDs skewed negative, with gains tending to reverse after the open.</li>
</ul>


Following HSCI's quarterly review in May 2026, we expect six names to become HK Connect eligible effective 8 June 2026.
Four of these names fell through the bridge window. Two recorded positions returned in the pre-implementation window.
Historically, the implementation-day opening has been the moment to capture. The full first week for prior Connect ADDs skewed negative, with gains tending to reverse after the open.


Beijing Haizhi Technology Group (2706 HK)

HSCI / HK Connect June 2026: Pre-Implementation Update

Z.AI

HSCI / HK Connect June 2026: Pre-Implementation Update